A single-arm, open-label, multicenter phase II trial (CheckMate 172) of nivolumab (NIVO) safety in European patients (pts) with advanced melanoma (MEL) who have progressed after ipilimumab therapy (IPI).

被引：0

作者：

Schadendorf, Dirk

Ascierto, Paolo Antonio

Espinosa, Enrique

Haanen, John B. A. G.

Hermann, Frank

Nathan, Paul D.

机构：

[1] Univ Hosp Essen, Essen, Germany

[2] Ist Nazl Tumori Fdn Pascale, Naples, Italy

[3] Univ Autonoma Madrid, Hosp Univ La Paz, Madrid, Spain

[4] Netherlands Canc Inst, Amsterdam, Netherlands

[5] Bristol Myers Squibb, Munich, Germany

[6] Mt Vernon Canc Ctr, London, England

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS9083

引用

页数：1